Neuropace, Inc. NPCE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.07M-17.0% | $26.59M-2.8% | $27.35M+16.3% | $23.52M+4.4% | $22.52M+4.9% | ||
| $4.02M-33.1% | $6.01M-2.8% | $6.19M+14.8% | $5.39M+4.0% | $5.18M-1.8% | ||
| $18.05M-12.3% | $20.58M-2.8% | $21.17M+16.7% | $18.13M+4.6% | $17.34M+7.1% | ||
| 81.8%+4.4pp | 77.4%0.0pp | 77.4%+0.3pp | 77.1%+0.1pp | 77%+1.6pp | ||
| $7.19M+2.3% | $7.03M+6.9% | $6.58M-3.9% | $6.85M-8.0% | $7.44M+23.0% | ||
| $11.58M+5.9% | $10.94M-13.2% | $12.6M+4.6% | $12.04M+9.5% | $11M+10.6% | ||
| $4.84M+10.5% | $4.38M-4.6% | $4.59M-24.3% | $6.07M+50.0% | $4.05M+5.4% | ||
| $23.62M+5.7% | $22.35M-6.0% | $23.77M-4.8% | $24.96M+11.0% | $22.49M+13.3% | ||
| $23.62M+5.7% | $22.35M-6.0% | $23.77M-4.8% | $24.96M+11.0% | $22.49M+13.3% | ||
| -$5.57M-215% | -$1.77M+32.0% | -$2.6M+61.9% | -$6.82M-32.6% | -$5.15M-40.9% | ||
| -25.2%-18.6pp | -6.6%+2.9pp | -9.5%+19.5pp | -29%-6.2pp | -22.9%-5.8pp | ||
| $1.52M-4.9% | $1.6M-2.7% | $1.65M-20.1% | $2.06M-4.4% | $2.15M-1.8% | ||
| $565K-11.4% | $638K-4.3% | $667K-7.1% | $718K-9.5% | $793K+16.4% | ||
| -$165K— | $0-100% | $82K+117% | -$486K-493% | -$82K— | ||
| -$6.69M-145% | -$2.73M+21.9% | -$3.5M+59.6% | -$8.65M-31.3% | -$6.59M-25.5% | ||
| -30.3%-20.0pp | -10.3%+2.5pp | -12.8%+24.0pp | -36.8%-7.5pp | -29.3%-4.8pp | ||
| -$0.20-150% | -$0.08+27.3% | -$0.11+57.7% | -$0.26-23.8% | -$0.21-23.5% | ||
| -$0.20-150% | -$0.08+27.3% | -$0.11+57.7% | -$0.26-23.8% | -$0.21-23.5% | ||
| 33.7M+3.0% | 32.7M-1.2% | 33.1M+0.8% | 32.9M+4.4% | 31.5M+8.1% | ||
| 33.7M+3.0% | 32.7M-1.2% | 33.1M+0.8% | 32.9M+4.4% | 31.5M+8.1% | ||
| -$165K— | $0-100% | $82K+117% | -$486K-493% | -$82K— | ||
| $22.07M-17.0% | $26.59M-2.8% | $27.35M+16.3% | $23.52M+4.4% | $22.52M+4.9% | ||
| -$5.57M-215% | -$1.77M+32.0% | -$2.6M+61.9% | -$6.82M-32.6% | -$5.15M-40.9% | ||
| -$5.51M-226% | -$1.69M+32.5% | -$2.5M+62.8% | -$6.72M-31.9% | -$5.1M-41.4% | ||
| -$5.51M-226% | -$1.69M+32.5% | -$2.5M+62.8% | -$6.72M-31.9% | -$5.1M-41.4% | ||
| -25%-18.6pp | -6.3%+2.8pp | -9.1%+19.4pp | -28.6%-6.0pp | -22.6%-5.8pp | ||
| -$5.57M-215% | -$1.77M+32.0% | -$2.6M+61.9% | -$6.82M-32.6% | -$5.15M-40.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neuropace, Inc.'s revenue?
- Neuropace, Inc. (NPCE) generated $99.5M in revenue over the trailing twelve months, up 18.1% year over year.
- Is Neuropace, Inc. profitable?
- Neuropace, Inc. is not currently profitable: it reported a net loss of $21.6M over the trailing twelve months, a -21.7% net margin.
- What are Neuropace, Inc.'s profit margins?
- Gross margin is 78.3% and operating margin is -16.8%, with a -21.7% net margin.
- What is Neuropace, Inc.'s earnings per share?
- Neuropace, Inc.'s diluted EPS over the trailing twelve months is $-0.65.
- Where does Neuropace, Inc.'s income statement data come from?
- Every line is extracted from Neuropace, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
